Skip to main content
. 2020 Jun 11;17(9):e255–e268. doi: 10.1016/j.hrthm.2020.06.010

Table 3.

Effect on QTc and proarrhythmia of experimental pharmacological therapies for COVID-1936

QTc prolongation TdP risk
Chloroquine37, 38, 39, 40 Moderate ↑ Low risk of TdP
Hydroxychloroquine41 Moderate ↑ Low risk of TdP
Azithromycin42, 43, 44, 45, 46, 47, 48 Moderate ↑ Very low risk of TdP
Lopinavir/ritonavir37 Moderate ↑ Low risk of TdP
Tocilizumab49 Mild ↑ or ↓ NR
Fingolimod Mild ↑ NR
Remdesivir NR NR
Interferon alfacon-1 NR NR
Ribavirin NR NR
Methylprednisolone NR NR

NR = not reported; TdP = torsade de pointes.